Effective: 10/01/13 p APPROVED BY: Pharmacy and Therapeutics Committee Page 1 of 5
|
|
- Alexandra Newton
- 5 years ago
- Views:
Transcription
1 APPROVED BY: Pharmacy and Theraeutics Committee Page 1 of 5 Purose: To rovide safe and effective anticoagulation theray for UH atients Policy: Uon order of a hysician, hearin low molecular weight hearin (LMWH) and/or oral warfarin theray will be administered according to the following rotocol. Procedure: I. Hearin Theray a. Indication for use will be documented in the chart. Indications include: i. Dee vein thrombosis iv. Atrial fibrillation with embolism v. Unstable angina vi. Periheral arterial embolism vii. Aortic and/or mitral valve relacement b. Patients with the following contraindications should not receive hearin theray: i. Hyersensitivity to hearin/lmwh ii. Active bleeding iii. Severe thrombocytoenia iv. Hearin-induced thrombocytoenia c. The following clinical information should be documented in the chart rior to initiation of theray: i. Patient age, weight, height, and gender ii. Medical and medication history ertaining to anticoagulation of the atient iii. Indication and duration for hearin theray iv. Laboratory baseline values 1. PT/INR, aptt, CBC, latelet count v. Order for no IM injections while on hearin theray d. Laboratory monitoring and dosing adjustments i. Reeat aptt 6 hours after the start of the hearin infusion and 6 hours after each dose adjustment. ii. Adjust bolus and infusion according to rotocol. iii. After two consecutive theraeutic aptt values, order daily am aptt. e. Physician notification i. The hysician must be notified if atient exeriences any bleeding.
2 APPROVED BY: Pharmacy and Theraeutics Committee Page 2 of 5 II. ii. The hysician must be notified in the event of significant adverse effect to hearin theray or if aptt is greater than 120. iii. The hysician should also be notified if the theray is not consistent with the duration of theray as documented in the chart. f. Pharmacy is resonsible for reviewing the orders for all hearin theray. g. All hearin rearations shall be of concentrations and volumes aroved by the P&T committee. h. All hearin infusions will be administered via rogrammable infusion ums. i. A rescriber s order is required for the use of all hearin roducts including hearin flush solutions. Low molecular weight hearin a. Indication for use will be documented on the chart. Indications include: i. Dee vein thrombosis iv. Atrial fibrillation with embolism v. Prohylaxis of stroke in ost MI atient vi. Unstable angina vii. Periheral arterial embolism viii. Aortic and/or mitral valve relacement b. Patients with the following contraindications should not receive LMWH theray: i. Hyersensitivity to hearin/lmwh ii. Active bleeding iii. Severe thrombocytoenia iv. Hearin-induced thrombocytoenia c. The following clinical information should be documented in the chart rior to initiation of theray: i. Patient age, weight, height, and gender ii. Medical and medication history ertaining to anticoagulation of the atient iii. Indication and duration for hearin theray iv. Laboratory baseline values 1. PT/INR, aptt, CBC, latelet count v. Order for no IM injections while on hearin theray d. Laboratory monitoring and dosing adjustments
3 APPROVED BY: Pharmacy and Theraeutics Committee Page 3 of 5 III. i. No routine monitoring is necessary for standard LMWH theray (rohylaxis or treatment doses) ii. For secialized oulations, (renal failure, regnancy, morbidly obese, atients less than 90% of ideal body weight) a single anti-xa level should be measured 3 to 4 hours after the first LMWH dose. e. Physician notification i. The hysician most be notified if atient exeriences any bleeding. ii. The hysician should also be notified if the theray is not consistent with the duration of theray as documented in the chart. f. Pharmacy is resonsible for reviewing the orders for all LMWH theray. g. A rescriber s order is required for the use of all LMWH roducts. Warfarin theray a. Indication for use will be documented in the chart. Indications include: i. Dee vein thrombosis iv. Atrial fibrillation with and without embolism v. Unstable angina vi. Artificial cardiac valve relacement vii. Selected cancer atients viii. Other warranted indications b. Clinical information which must be documented in the chart rior to initiation of theray: i. Indication ii. Duration iii. Theraeutic range iv. Patient age v. Medication history including revious anticoagulation theray vi. Nutritional status vii. Concurrent disease states c. Monitoring i. International Normalized Ration (INR) is used to monitor and modify doses of warfarin. ii. Baseline PT/INR must be obtained for all atients before initial dose or dosing change is ordered
4 APPROVED BY: Pharmacy and Theraeutics Committee Page 4 of 5 iii. For new atients, INR should be monitored daily until theraeutic for 2 consecutive days. Subsequently, INR should be measured 2-3 times weekly for two weeks, then weekly if stable. d. General information i. Warfarin may be started on the first day of hearin/lmwh theray ii. When converting from hearin/lmwh, warfarin may be overlaed. iii. Warfarin will be disensed one dose at a time and administered at 4PM daily unless secifically indicated otherwise. e. Patient education i. A harmacist will rovide atient education on the safe and effective use of warfarin theray. Each atient will be educated based uon the atient s level of comrehension. Documentation of the education session and comrehension will be documented in the chart. Patient education will include the following: 1. Medication name, strength and descrition 2. Daily dosage and administration times 3. How to handle missed doses 4. Purose of the medication and how it works 5. Dietary and medication interactions 6. Recognition of signs of bleeding and aroriate rocedures to follow 7. Imortance of comliance with medication regimen and clinic aointments 8. Keeing ID indicating warfarin use 9. Imortance of alerting rescriber when regnant, if aroriate ii. Nutritional services may be consulted for additional education f. Outatient anticoagulation theray management i. An anticoagulation service will be rovided within the University Health Shreveort Medicine Clinic. 1. Patients may be referred to this service through the electronic health record 2. Policies and rotocols for this anticoagulation service will be reviewed by the P&T Committee on an annual basis.
5 APPROVED BY: Pharmacy and Theraeutics Committee Page 5 of 5 IV. ii. Physicians who choose to manage their own atient s anticoagulation theray will be required to submit a clinic-secific olicy to the P&T committee for aroval on an annual basis. Anticoagulation theray outcome measures a. The following criteria will be evaluated for at least 12 randomly selected atients er quarter. A summary will be resented to the P&T committee every 6 months. i. INR is in theraeutic range for atient s condition ii. There are no bleeding eisodes iii. There are no thrombotic comlications iv. Interventions with hysicians regarding atient theray v. Number of atients with INR greater than 6.0 vi. Number of atients with INR less than 1.5
Clinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationBassett Healthcare Clinical Laboratory
Therapeutic Drug Level Collection Guidelines Anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid) Consider collecting after steady state conditions are reached, i.e.
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationUniversity Health System
Q University Health System Community Medicine Associates COMMUNITY MEDICINE ASSOCIATES PROTOCOL CMA PR 12-11.0204 Protocol For: Definition: Anticoagulation Management Protocol for MLP and PharmD To document
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More informationDraft Guidance on Dapsone
Contains Nonbinding ecommendations Draft Guidance on Dasone his draft guidance, when finalized, will reresent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this toic.
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationRisk factors for superficial wound complications in hip and knee arthroplasty
ORIGINAL ARTICLE INFECTIOUS DISEASES Risk factors for suerficial wound comlications in hi and knee arthrolasty K. Carroll 1, M. Dowsey 1,2, P. Choong 1,2 and T. Peel 2,3 1) Deartment of Orthoaedics, St
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationUsing an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy
Using an anti-xa level nomogram to adjust intravenous unfractionated heparin infusion for arrhythmia in pregnancy W. Sia, E. Toor, N. Wahab, J. Windram, R. Khurana Cardiac Problems in Pregnancy Congress
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationThe Efficacy of Tranexamic Acid Versus Epsilon Amino Caproic Acid in Decreasing Blood Loss in Patients Undergoing Mitral Valve Replacement Surgery
Journal of Anesthesiology 2017; 5(2): 11-18 htt://www.scienceublishinggrou.com/j/ja doi: 10.11648/j.ja.20170502.12 ISSN: 2376-7766(Print); ISSN: 2376-7774(Online) The Efficacy of Tranexamic Acid Versus
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationThrombocytopenia After Aortic Valve Replacement With Freedom Solo Bioprosthesis: A Propensity Study
Thrombocytoenia After Aortic Valve Relacement With Freedom Biorosthesis: A Proensity Study Alessandro Piccardo, MD, Dan Rusinaru, MD, Benoit Petitrez, MD, Paul Marticho, MD, Ioana Vaida, MD, Christohe
More informationAnticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics
MPharm Programme & OSPAP Programme Anticoagulation Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics tania.jones@sunderland.ac.uk Lecture MPHM13 / MPHM14 2017-2018 MPHM13 & MPHM14 Objectives
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationGuideline for Treatment of Head Injury in the Anticoagulated Patient
Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS. ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS I. Purpose : A. To reduce morbidity and mortality associated
More informationDepartment of Pharmacy Practice, Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India, 2
Vol 9, Issue 1, 2016 ISSN - 0974-2441 Research Article IMPACT OF CONTINUOUS PATIENT COUNSELLING ON KNOWLEDGE, ATTITUDE, AND PRACTICES AND MEDICATION ADHERENCE OF DIABETIC PATIENTS ATTENDING OUTPATIENT
More informationNursing Process Focus: Patients Receiving Heparin
Obtain complete heath history including allergies, drug history and possible drug Assess baseline coagulation studies and CBC. Assess for history of bleeding disorders, GI bleeding, cerebral bleed, recent
More informationChallenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest
Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationNitroglycerin and Heparin Drip Interfacility Protocols
Nitroglycerin and Heparin Drip Interfacility Protocols EMS Protocol This protocol applies to nitroglycerin and Heparin drips that are initiated at the transferring facility prior to transport and are not
More informationGuidelines for Anticoagulation in Paediatric Cardiac Patients
Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationIncorporated Dosing Guidelines: Intravenous Heparin Therapy Initial Dose
Intravenous Heparin Therapy Initial Dose (Max Dose) IV Infusion Rate IV Infusion Rate (Max Dose) Lab Tests High Dose 80 units/kg 8,000 units 18 units/kg/hr 1,800 units/hr Intermediate Dose 5,000 units
More information2018 Early Management of Acute Ischemic Stroke Guidelines Update
2018 Early Management of Acute Ischemic Stroke Guidelines Update Brandi Bowman, PhC, Pharm.D. April 17, 2018 Pharmacist Objectives Describe the recommendations for emergency medical services and hospital
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationWarfarin in Adults : Guidelines for the use of. These guidelines apply to all patients commenced or continuing on warfarin
Warfarin in Adults : Guidelines for the use of Document Type: Clinical Guideline Clinical Lead: Ian Neilly Author/s: Ian Neilly/Paul Barbieri Directorate: Haematology Approved by Haematology Specialty
More informationSAVAYSA (edoxaban tosylate) oral tablet
SAVAYSA (edoxaban tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationDr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust
MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationImpact of Severe Postoperative Complications after Cardiac Surgery on Mortality in Patients Aged over 80 Years
Ann Thorac Cardiovasc Surg 2014; 20: 383 389 Online July 31, 2013 doi: 10.5761/atcs.oa.13-02268 Original Article Imact of Severe Postoerative Comlications after Cardiac Surgery on Mortality in Patients
More informationGUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE
2018 UPDATE QUICK SHEET 2018 American Heart Association GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE A Summary for Healthcare Professionals from the American Heart Association/American
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationCARDIAC REHABILITATION PROGRAMME:- MEDICATION
CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationLa gestione dell ictus ischemico o emorragico nel paziente sotto NAO
La gestione dell ictus ischemico o emorragico nel paziente sotto NAO Antonio Carolei e Cindy Tiseo Clinica Neurologica e Stroke Unit Avezzano - Sulmona Università degli Studi dell Aquila Abano Terme, 10
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More information6 semanas de embarazo. Critical pt inr levels. Inicio / Embarazo / 6 semanas de embarazo
Inicio / Embarazo / 6 semanas de embarazo 6 semanas de embarazo Critical pt inr levels INR is the result of the patient PT/mean normal PT, exponentially equalized by the ISI. INR levels above 4.9 are considered
More informationAbstract. Med. J. Cairo Univ., Vol. 84, No. 1, March: 77-83,
Med. J. Cairo Univ., Vol. 84, No. 1, March: 77-83, 2016 www.medicaljournalofcairouniversity.net Effects on the Maternal Nausea and Vomiting after Giving Prohylactic Ehedrine Versus Phenylehrine for Prevention
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationNorth East Essex Medicines Management Committee
Colchester Hospital University NHS Foundation Trust North East Essex Clinical Commissioning Group North East Essex Medicines Management Committee ORAL ANTICOAGULANT (Vit K antagonist only) MANAGEMENT GUIDELINES
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationRelative Role of Factors Associated With Cerebral Infarction and Cerebral Hemorrhage
STROKE VOL, No 1, JANUARY-FEBRUARY. Eklof B, Lassen NA, Nilsson L, et al: Regional cerebral blood flow in the rat, measured by the tissue samling technique. Acta hysiol Scand 1: 1-,. Nilsson B: Measurement
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationThe risks of blood transfusion are well known. Aprotinin
Ultra-Low Dose Arotinin Decreases Transfusion Requirements and Is Cost Effective in Coronary Oerations Rebecca J. Dignan, MD, David W. Law, BSc, Peng W. Seah, MBBS, Con W. Manganas, MBBS, David C. Newman,
More informationHeparin Drip. Ordering
Heparin Drip Ordering Nurse entering of Heparin drip orders for physicians should only occur in situations when it is not feasible for the physician to enter orders directly Select the Heparin IV Drip
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationPrimary Stroke Center Acute Stroke Transfer Guidelines When to Consider a Transfer:
When to Consider a Transfer: Hemorrhagic Stroke Large volume intracerebral hematoma greater than 5cm on CT Concern for expanding hematoma Rapidly declining mental status, especially requiring intubation
More informationOral anti-thrombotic therapy-management in patients requiring endoscopy
Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationSyncope in Children and Adolescents
Aril 1997:1039 45 1039 Syncoe in Children and Adolescents DAVID J. DRISCOLL, MD, FACC, STEVEN J. JACOBSEN, MD, PHD, CO-BURN J. PORTER, MD, FACC, PETER C. WOLLAN, PHD Rochester, Minnesota Objectives. The
More informationTitle: Correlates of quality of life of overweight and obese patients: a pharmacy-based cross-sectional survey
Author's resonse to reviews Title: Correlates of quality of life of overweight and obese atients: a harmacy-based cross-sectional survey Authors: Laurent Laforest (laurent.laforest@chu-lyon.fr) Eric Van
More informationKey words: Diabetes Mellitus, HbA1c, Insulin, Sulfonylureas, Metformin. DOI: /jyp
J Young Pharm, 2018; 10(4) : 471-475 A multifaceted eer reviewed journal in the field of Pharmacy www.jyoungharm.org www.hcog.net Original Article Comarison of Insulin, Sulfonylurea and Sulfonylureas-Metformin
More informationThis was a randomised, double-blind, vehicle-controlled, with intra-individual comparison, single centre study.
Final Reort No. MCB 0202 FRI October 24 111,2003 2 SYNOPSIS Study title: Reeat insult atch test with Daivobet!Dovobet Ointment - A Protocol number: Studied eriod: First subject in (inclusion): First study-drug
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationPaediatric Anticoagulant Guidelines. Bhavee Patel, Gareth Thomas
Paediatric Anticoagulant Guidelines Author: Bhavee Patel, Gareth Thomas Specialty: Paediatrics Date Approved: 18 th July 2012 Approved by: W&CH Quality & Safety Group Date for Review: June 2015 PAEDIATRIC
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationA guide to anticoagulation management and self-testing
A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,
More informationThe control patients had at least the combination of cardiovascular failure necessitating vasoactive
ELECTRONIC SUPPLEMENTARY MATERIAL Material and methods Patients The control patients had at least the combination of cardiovascular failure necessitating vasoactive medication, respiratory failure necessitating
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationCARD THORACOTOMY PRE-OP PLAN
CARD THORACOTOMY PRE-OP PLAN PHYSICIAN S Diagnosis Weight Allergies Patient Care Perform Oral Care Perform night before surgery. Brush teeth with toothpaste, then swish and spit 15 ml chlorhexidine mouth
More informationCOPD is a common disease. Over the prolonged, Pneumonic vs Nonpneumonic Acute Exacerbations of COPD*
vs Acute Exacerbations of COPD* David Lieberman, MD; Devora Lieberman, MD; Yevgenia Gelfer, MD; Raiesa Varshavsky, MD; Bella Dvoskin, MD, PhD; Maija Leinonen, PhD; and Maureen G. Friedman, PhD Study objective:
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationcarinzz prophylactic regimens
Genitourin Med 1997;73:139-143 Continuing medical education HIV Eidemiology Unit, Chelsea and Westminster Hosital, 369 Fulham Road, London SW10 9TH, UK P J Easterbrook Acceted for ublication 8 October
More information